Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
There is a growing body of evidence suggesting that animal models can be developed to probe the specific domains of bipolar disorder (BD) using the endophenotype approach. Here we tested clinically active antimanic drugs to validate amphetamine-induced hyperactivity in Black Swiss mice as a putative model of the manic phase of BD. We also co-administered a mood stabilizer and an atypical antipsychotic drug in a manner akin to the clinical treatment regimens. Since lithium has been shown to potentially act through glycogen synthase kinase-3 (GSK3) inhibition, we evaluated the efficacy of selective GSK3 inhibitors in this model. Habituated animals were pretreated with a compound of interest before being challenged with amphetamine (2.0 mg/kg) and returned to activity cages for an additional 1.5 h. We tested lithium, sodium valproate, carbamazepine, olanzapine, ziprasidone as well as co-administered lithium and olanzapine at sub-efficacious doses. The GSK3 inhibitors tested included indirubin, alsterpaullone, TDZD-8, AR-A014418, SB-216763, and SB-627772. All mood stabilizers and antipsychotic drugs reduced hyperactivity without affecting spontaneous locomotion. While subactive doses of lithium and olanzapine were without effect, their co-administration produced robust reductions in hyperactivity. All GSK3 inhibitors were active in the model, producing selective inhibition of rearing hyperactivity. These data support the predictive validity of the model for the acute manic phase of BD and may have utility as an in-vivo model for identifying novel antimanic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis
McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., Marquez, R., & Alessi, D. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600633 · Cited by 594 · cited 1×
“In contrast, maintaining a high level of GSK3 activity as in GSK3a/b knockin mice (McManus et al. 2005) reduced spontaneous rearing and digging behaviours (Mines et al.”
BackgroundOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Toward constructing an endophenotype strategy for bipolar disorders
Hasler, G., Drevets, W. C., Gould, T. D., Gottesman, I. I., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.006 · Cited by 423
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300
Ralph, R. J., Paulus, M. P., Fumagalli, F., Caron, M. G., & Geyer, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00305.2001 · Cited by 271 · cited 1×
“2006) and by DAT KO mice (Giros et al. 1996 ; Ralph et al. 2001 ; Ralph-Williams et al. 2003 ; Zhuang et al. 2001).”
BackgroundHow can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
Brain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients
Anand, A., Verhoeff, P., Seneca, N., Zoghbi, S. S., Seibyl, J. P., Charney, D. S., & Innis, R. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1108 · Cited by 222
Cited by
Dopamine receptors –IUPHAR R eview 13
Beaulieu, J., Espinoza, S., & Gainetdinov, R. R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12906 · Cited by 521
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
McCarthy, M. J., Gottlieb, J. F., Gonzalez, R., McClung, C. A., Alloy, L. B., Cain, S., Dulcis, D., Etain, B., Frey, B. N., Garbazza, C., et al. (2022) · Bipolar Disorders · doi:10.1111/bdi.13165 · Cited by 136
Animal models of bipolar mania: The past, present and future
Logan, R. W., & McClung, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.041 · Cited by 136
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
“Additionally, GSK-3 inhibitors reduce the locomotor hyperactivity in amphetaminetreated animals, in DAT knockout mice and the behavioral aberrations induced by ketamine (Gould et al. 2004; Kalinichev and Dawson 2011; Chan et al. 2012).”
Background
Metadata
- Authors
- Kalinichev, M., & Dawson, L. A.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-06
- Volume
- 14
- Issue
- 08
- Pages
- 1051-1067
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2149104590
- Cited by
- 68
- References
- 10
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. https://app.cochat.ai/papers/10.1017/s1461145710001495
- The paper
- Kalinichev, M., & Dawson, L. A. (2011). Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145710001495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.